Floatz logo

Glucose-Dependent Insulinotropic Polypeptide

Type 2 Diabetes

Esbjerg Hospital - University Hospital of Southern Denmarkprotein_peptidePhase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Glucose-Dependent Insulinotropic Polypeptide is also rated in:

fatty liver diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CC
Indicative ·
47 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →